Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4250-4256

  Ando, Izuru ^a   Adachi, Tsuyoshi ^a   Ogura, Naoki ^a   Toyonaga, Yukiyo ^a   Sugimoto, Kazuyuki ^a   Abe, Hiroyuki ^a   Kamada, Masafumi ^a   Noguchi, Toru ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; ALPHA INTERFERON; DACLATASVIR; FILIBUVIR; JTK 853; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5A; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; SHORT HAIRPIN RNA; SIMEPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME STRUCTURE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NUCLEOTIDE BINDING SITE; PALM BINDING SITE; PRIORITY JOURNAL; REPLICON; STRUCTURE ANALYSIS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; BINDING SITES; CELL LINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PIPERAZINES; PROTEIN STRUCTURE, QUATERNARY; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84864378871     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00312-12     Document Type: Article

References (41)

1. Adachi T, et al. 2002. The essential role of C-terminal residues in regulating the activity of hepatitis C virus RNA-dependent RNA polymerase. Biochim. Biophys. Acta 1601:38-48. (Pubitemid 38234529)
2. Ali S, et al. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52:4356-4369.
3. Alter MJ. 2007. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13:2436-2441. (Pubitemid 46929498)
4. Beaulieu PL. 2009. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin. Ther. Pat. 19:145-164.
5. Behrens S-E, Tomei L, De Francesco R. 1996. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22. (Pubitemid 26020384)
6. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190. (Pubitemid 36228102)
7. Choo QI, et al. 1991. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 88:2451-2455.
8. Coelmont L, et al. 2006. Ribavirin antagonizes the in vitro anti-Hepatitis C virus activity of 2=-C-methylcytidine, the active component of valopicitabine. Antimicrob. Agents Chemother. 50:3444-3446. (Pubitemid 44527521)
9. De Francesco R, Behrens SE, Tomei L, Altamura S, Jiricny J. 1996. RNA-dependent RNA polymerase of hepatitis C virus. Methods Enzymol. 275:58-67. (Pubitemid 26336916)
10. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitisCvirus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650.
11. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. U. S. A. 88:5547-5551. (Pubitemid 21914782)
12. Hijikata M, et al. 1993. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 67:4665-4675. (Pubitemid 23215946)
13. Hijikata M, et al. 1993. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 90:10773-10777. (Pubitemid 23347125)
14. Hirashima S, et al. 2007. Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety. Bioorg. Med. Chem. Lett. 17:3181-3186. (Pubitemid 46702610)
15. Hirashima S, et al. 2006. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 49:4721-4736. (Pubitemid 44162700)
16. Howe AY, et al. 2008. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 52:3327-3338.
17. Howe AY, et al. 2006. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor. Antimicrob. Agents Chemother. 50:4103-4113. (Pubitemid 44865155)
18. Ikegashira K, et al. 2006. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. J. Med. Chem. 49:6950-6953. (Pubitemid 44885982)
19. Ishida T, et al. 2006. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole. Bioorg. Med. Chem. Lett. 16:1859-1863. (Pubitemid 43267365)
20. Kato N, et al. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. U. S. A. 87:9524-9528. (Pubitemid 120016475)
21. Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624. (Pubitemid 32381503)
22. Lenz O, et al. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54:1878-1887.
23. Lohmann V, Körner F, Dobierzewska A, Bartenschlager R. 2001. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:1437-1449. (Pubitemid 32094702)
24. Lohmann V, Körner F, Herian U, Bartenschlager R. 1997. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71:8416-8428. (Pubitemid 27446422)
25. Lohmann V, et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. (Pubitemid 29307577)
26. Migliaccio G, et al. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
27. Naviaux RK, Markusic D, Barshop BA, Nyhan WL, Haas RH. 1999. Sensitive assay for mitochondrial DNA polymerase γ. Clin. Chem. 45:1725-1733. (Pubitemid 29477328)
28. Okamoto H, et al. 1991. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J. Gen. Virol. 72:2697-2704.
29. Prichard MN, Prichard LE, Shipman C, Jr. 1993. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-206.
30. Rodriguez-Torres M, et al. 2011. Abstr. HEP DART 2011: frontiers in drug development for viral hepatitis, abstr 57. IHL Press, Tucker, GA.
31. Sarrazin C, et al. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. (Pubitemid 46677938)
32. Shaw AN, et al. 2009. Substituted benzothiadizine inhibitors of hepatitis C virus polymerase. Bioorg. Med. Chem. Lett. 19:4350-4353.
33. Shi ST, et al. 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 53:2544-2552.
34. Takamizawa A, et al. 1991. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65:1105-1113.
35. Takeuchi T, et al. 1999. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 16:636-642. (Pubitemid 29106771)
36. Tellinghuisen TL. 2011.Anoverview of the hepatitisCvirus life cycle, p 1-48. In Tan SL, YupengH(ed), Hepatitis C: antiviral drug discovery and development. Caister Academic Press, Hethersett, Norfolk, United Kingdom.
37. Tomei L, et al. 2003. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77:13225-13231. (Pubitemid 37494318)
38. Tong CY, Gilmore IT, Hart CA. 1995. HCV-associated liver cancer. Lancet 345:1058-1059.
39. Wakita T, et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. (Pubitemid 41021213)
40. Yang G, et al. 2007. Highly selective action of triphosphate metabolite of 4=-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res. 73:185-191.
41. Zein NN. 2000. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13:223-235. (Pubitemid 30205426)